Metagenomi Therapeutics, Inc.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$221M
↓-31.9% -$103Mvs FY2024
Total Liabilities
$63M
↓-30.3% -$27Mvs FY2024
Equity
$159M
↓-32.5% -$76Mvs FY2024
Cash
$42M
↑+52.3% +$14Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $221M | $325M |
| Current Assets | $166M | $258M |
| Cash | $42M | $27M |
| ST Investments | $0 | $0 |
| Receivables | $0 | $1M |
| Inventory | $0 | $0 |
| Other Current | $124M | $229M |
| Non-Current Assets | $56M | $67M |
| PPE | $12M | $18M |
| Goodwill | $0 | $0 |
| Intangibles | $0 | $0 |
| Investments | $2M | $3M |
| Other Non-Current | $41M | $45M |
| Total Liab+Eq | $221M | $325M |
| Current Liab. | $23M | $37M |
| Accounts Payable | $1M | $533K |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $9M | $23M |
| Other CL | $13M | $14M |
| Non-Current Liab. | $40M | $52M |
| Long-Term Debt | $0 | $0 |
| Other LT Liab. | $40M | $52M |
| Equity | $159M | $235M |
| Retained Earnings | $311M | $223M |
| Other Equity | $0 | $12M |
QuarterCharts · SEC EDGAR data · MGX · Comparing FY2025 vs FY2024